Trial reportThe Journal of clinical endocrinology and metabolism2011
Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00640224 (Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Obesity, Insulin Resistance, and Bone Metabolism in Adolescents With PCOS: Effects of Insulin Sensitizers Versus Oral Contraceptives
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Obesity disrupts ILC2 metabolic and functional homeostasis by inhibiting mTORC1 signaling.Cellular & molecular immunology · 2026Article
- Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS.Journal of clinical medicine · 2022Review
- Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.Endocrine · 2022Review
- Markers of insulin resistance in Polycystic ovary syndrome women: An update.World journal of diabetes · 2022Review
- Article
- Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.International journal of molecular sciences · 2019Review
- Polycystic Ovary Syndrome in Adolescents: Challenges in Diagnosis and Treatment.International journal of endocrinology and metabolism · 2019Review
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome.Therapeutic advances in endocrinology and metabolism · 2019Review
- Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome.The Journal of clinical endocrinology and metabolism · 2018Article
- Combined Oral Contraceptive Effects on Low-Grade Chronic Inflammatory Mediators in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.International journal of inflammation · 2018Review
- Increased Adrenal Androgens in Overweight Peripubertal Girls.Journal of the Endocrine Society · 2017Article
- Anti-Müllerian Hormone in Obese Adolescent Girls With Polycystic Ovary Syndrome.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2017Article
- The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.Diabetes care · 2016Article
- Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome.Fertility and sterility · 2016Article
- Early Biomarkers of Subclinical Atherosclerosis in Obese Adolescent Girls with Polycystic Ovary Syndrome.The Journal of pediatrics · 2016Article
- Cardiovascular risk factors and events in women with androgen excess.Journal of endocrinological investigation · 2015Review
- PCOS in adolescence and type 2 diabetes.Current diabetes reports · 2015Review
- Hyperinsulinaemic androgen excess in adolescent girls.Nature reviews. Endocrinology · 2014Article
- Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile.Fertility and sterility · 2013Article
- Contraception quandaries: oral contraceptive decisions in the pediatric endocrinology office.The Journal of clinical endocrinology and metabolism · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
contextAdolescents with polycystic ovary syndrome (PCOS) have insulin resistance and higher rates of the metabolic syndrome.
objectiveOur objective was to compare the effects of 6 months treatment with drospirenone/ethinyl estradiol (EE) (3 mg/30 μg) vs. rosiglitazone (4 mg) daily on the hormonal and cardiometabolic profiles of overweight/obese adolescents with PCOS.
designWe conducted a randomized, double-blinded, parallel clinical trial in an academic hospital, with n = 46 patients. OUTCOME MEASURES: The primary outcome measure was insulin sensitivity, hepatic with [6,6-(2)H(2)]glucose and peripheral with a 3-h hyperinsulinemic-euglycemic clamp. Other outcome measures included plasma androgen profile and response to ACTH stimulation, glucose and insulin response to oral glucose tolerance test, insulin secretion with a 2-h hyperglycemic clamp, fasting lipid profile, inflammatory markers, intima media thickness, aortic pulse wave velocity, body composition by dual-energy x-ray absorptiometry, and abdominal adiposity by computed tomography scan.
resultsDrospirenone/EE resulted in greater reductions in androgenemia. Neither treatment led to change in weight or body mass index, but rosiglitazone led to a significant decrease in visceral adiposity. Compared with drospirenone/EE, treatment with rosiglitazone improved hepatic and peripheral insulin sensitivity and lowered fasting and stimulated insulin levels during the oral glucose tolerance test. Treatment with drospirenone/EE was associated with elevations in total cholesterol, high-sensitivity C-reactive protein and leptin concentrations, whereas treatment with rosiglitazone led to lower triglycerides and higher adiponectin concentrations. Neither treatment affected intima media thickness or pulse wave velocity.
conclusionsIn overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia. Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.